Active Biotech AB (BTP)

Profile

https://www.activebiotech.com

Active Biotech AB is a Swedish biotechnology company focused on developing pharmaceutical products that modulate the immune system. Headquartered in Lund and founded in 1983, the company concentrates on treatments for cancer and inflammatory diseases, particularly inflammatory eye disorders. Its current portfolio centers on three key projects: Tasquinimod, a small-molecule immunomodulator studied in multiple myeloma; Laquinimod, aimed at inflammatory eye conditions such as uveitis; and Naptumomab, an antibody-based immunotherapy targeting solid tumors. Active Biotech operates in the research and development segment of the healthcare market, working primarily through clinical-stage collaborations and licensing arrangements with larger pharmaceutical partners. By focusing on specialist indications with significant unmet medical need, the company plays a niche role within the global biopharmaceutical ecosystem, contributing novel immune-modulating therapies that may complement existing oncology and immunology treatment paradigms.